Neutral to Not so Good Results for Q.E and Year Ending 31.03.2025 - Gland Pharma Ltd

BSE: 543245 NSE:

Gland Pharma reports Revenue of Rs Rs 56,165 Mn for FY25 With improved Gross Profit Margin. other details as below a) Recommends final dividend of Rs 18 per share b) Revenue = Decreased by 7% YoY ( increased by 3% QoQ.) c) EBITDA = Decreased by 3% YoY & QoQ. d) EBITDA = Margin increased by 100 bps to 24% in Q4FY25. e) PAT = Decreased by 3% YoY and ( 9% QoQ). f) PAT = margin was 13%, same as in Q4 FY24 and 15% in Q3 FY25.